Serum Levels of Angiopoietin-2 and C-Reactive Protein in Chronic Myeloid Leukaemia Patients: Relation to Different Phases of the Disease

NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA-CHRONIC PHASE

Patched Homolog Gene (PTCHI) As a Reliable Marker for Predicting Imatinib Response in Chronic Phase Chronic Myeloid Leukemia Patients in Correlation with Early Response to First

Association of Microrna-153-3p Expression in Response to Treatment with Imatinib in Patients with Chronic Myeloid Leukemia

Study and Survey of BCR-ABL Transcript Types in Chronic Myeloid Leukemia (CML) Young Egyptian Patients

Study of PTCH1 Gene as a Prognostic Marker to Predict Imatinib Response in CML Patients: a Single Egyptian Center Experience

The relation between multidrug resistance gene (MDR1) polymorphism and response to tyrosine kinase inhibitors (TKIS) in patients with chronic myeloid leukemia (CML)

Assessment of Response of Chronic Phase CML to Imatinib treatment

P-Stat3Tyr705 expression in different cell population in chronic myeloid leukemia by flowcytometry

Therapeutic Efficacy of Tyrosine Kinase Inhibitors Treatment for Metastatic Renal Cell Carcinoma Using 18F-FDG PET/CT